By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Synthetic Genomics and New England Biolabs announced on Tuesday a non-exclusive licensing agreement for the commercialization of the Gibson Assembly Master Mix.

The deal calls for NEB to commercialize the product, which is based on the Gibson Assembly method, developed by Daniel Gibson and colleagues at the J. Craig Venter Institute as part of a program sponsored by Synthetic Genomics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.